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Assessment of immune responses to SARS-CoV-2, the virus responsible for COVID-19,
is based almost entirely on the antibody response, and apart from clinical trials, compar-
isons of the merits of one vaccine versus another, or of the first jab versus the second, or
the immunity of individuals resulting from infection are all based on antibodies specific for
the viral spike or S protein. Broadly speaking such antibodies are measured by a lateral
flow test or similar in which antibody binds to the viral S protein, a test which is fast but
non-quantitative and gives no indication of antibody function. Alternatively, there is the
more labour-intensive neutralization test which measures the ability of antibody to inhibit
virus infectivity in cell culture, under conditions that do not mimic the in vivo situation.
Both types of tests give information of limited value and say nothing about the epitope
specificity of antibodies present.
1. The Epitope Landscape
The virus surface protein of an enveloped virus like COVID-19 possesses a small
number of antigenic sites—influenza A virus has three or four [1]—each comprising an
array of epitopes composed of a small number of amino acids, with each epitope recognised
by an antibody with a unique specificity (or paratope). Thus, if an individual responds
to every epitope s/he would have a diverse population of antibodies each recognising
a different facet of the S protein. In addition, there would be a variable amount of each
antibody present, and each antibody would have different biological properties, varying
in its ability to neutralize virus infectivity and the mechanism by which that was brought
about (e.g., some inhibit virus attachment to the cell receptor, some inhibit post-attachment
functions like fusion, while others are non-neutralizing). In addition, there are nine isotypes
of human antibody defined by a unique C-terminal unvarying sequence that is not involved
in epitope-binding. In theory all nine isotypes could form antibodies that are all specific for
the same epitope. This is important as each isotype has evolved to protect different regions
of the body and has evolved specialised functions to combat different pathogens.
However, in reality the likelihood is that different individuals produce antibodies
to only a fraction of the number of epitopes present and that different individuals, being
genetically heterogeneous, will respond with a different spectrum of antibodies. Unfortu-
nately, we do not know this for sure as such information is not available and to the author’s
knowledge is not being sought. The best test available, the neutralization test, merely
averages out the neutralizing capacity of all the antibodies possessed by an individual, and
gives no information about the range of antibodies present. To take an extreme example,
an individual with 1 unit of each of antibodies specific for 10 different epitopes will give
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the same neutralization titre as another individual with 10 units of antibody specific for
just 1 epitope. The consequences of the latter are far-reaching and are discussed below.
2. Assessing the Risk of Viral Variants
Knowledge of the range of neutralizing antibody specificities present in a country’s
population is relevant to both assessing the risk posed by variant viruses that bear amino
acid substitutions in the S protein, and in understanding the role of neutralizing antibody
in the evolution of virus variants. Let us suppose that a mutation results in a coding change
that fundamentally alters an epitope so that the relevant antibody no longer recognises it.
Providing that an individual has antibodies to other unchanged neutralizing epitopes that
variant will be neutralized. For example, the S protein of the COVID-19 variant B.1.1.7 has
eight mutations including the N501Y substitution in the receptor-binding domain and
was tested for its ability to be neutralized by a panel of 12 monoclonal antibodies (MAbs)
prepared against wild-type virus: of these the neutralizing activity of ten MAbs was
unchanged, one had reduced activity and the activity of one was increased [2]. Problems
would arise, however, if an individual made only one neutralizing antibody and that
was directed against the mutated epitope. The variant virus will not be neutralized
and the individual will be re-infected. This situation could apply to people who have
recovered from infection or have received one of the COVID-19 vaccines. However, a
limited number of convalescent sera (n = 20) fully neutralized B.1.1.7, although most
(16/20) had reduced activity against B.1.351, a variant with nine S protein mutations
including a D614G substitution [3].
The significance of a very narrow antibody response comes from studies with MAbs.
RNA viruses in general have a high mutation rate and a virus species such as COVID-
19 comprises a mixture of differing RNA genomes called a quasi-species. If one of these
variants is fitter and has a replication advantage, it will become a major component in the
quasispecies.
3. Antibody Responses Can Be Very Narrow
A virus antibody-resistant variant or escape mutant emerges as a result of selection
pressure from a single neutralizing MAb but, if the virus (such as influenza A) is incubated
simultaneously with two neutralizing MAbs directed against different non-overlapping
epitopes, no resistant variant emerges. The latter happens only when the second MAb
is diluted to a critical low concentration [4]. The reason for this lies in the mutation rate,
which is approximately 1 nucleotide change in every 100,000 nucleotides synthesised
per round of influenza genome replication or 10−5. It follows that the chance of a single
virus particle escaping neutralization by MAbs to two discrete epitopes is 10−10 and is
vanishingly unlikely. However, if an antibody-resistant mutant/variant to one of the MAbs
already exists in the population, then it has only to undergo a single mutation to escape
the second MAb. Thus, a mixture of three MAbs to discrete epitopes is the minimum
required to prevent the emergence of a neutralizing antibody-resistant mutant. The same
logic underlies the use of a cocktail of three HIV-1 antivirals, each acting on a different
virus target, to prevent drug-resistant mutants arising.
As mentioned earlier it is generally assumed that a normal immune response to an
infection or a vaccine comprises a plethora of antibodies specific to different epitopes in
approximately equal amounts. If so, no antibody-selected variants should ever arise. With
a ‘weak immune response’ (to two or more discrete neutralizing epitopes) there might be a
failure to prevent infection and a breakthrough of replication by the whole virus population,
but no variants would be produced. However, the fallacy lies in the assumption that no
individual produces an antibody response which is dominated by antibody to just one
epitope. In experiments in which mice and rabbits were conventionally immunized with
two or more doses of an inactivated influenza A virus vaccine it was found that sera from
11% mice and 75% rabbits mixed with virus and grown in embryonated eggs, selected
virus that escaped neutralization. In other words, these serum antibody responses were
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functionally monoclonal [4,5]. Serial bleeds taken after vaccination showed that there
was either a biased response from the get-go or it evolved only later [6]. Antiserum-
resistant variant virus no longer reacted with one of a panel of MAbs, and nucleotide
sequencing showed that it was a genuine antibody-resistant mutant. The HA-specific
antibody responses in mice and rabbits were biased to different antigenic sites. The
situation with COVID-19 is exacerbated by the appearance of virus variants with a changed
epitope landscape, so that what was a broad antibody response to the original virus
becomes a narrow response to the variant.
Few data are available for the human population although a restricted antibody
response to influenza infection has been observed in children [7,8] and adults [9,10]. A
relatively broad response was found in infected adults [8,11]. However, we as individuals
are genetically heterogeneous and it is unlikely that everyone will make the same spectrum
of antibodies [12,13]. The antibody response after administration with any of the approved
inactivated influenza vaccines is largely HA-specific and narrow in character [11,14], but
whether it is as narrow as was found above in mice and rabbits is not known. Naturally
occurring, clinically significant influenza A virus antigenic drift variants that can infect
people who have previously been infected, have four or more changes in two or more
antigenic sites, and take around 4 years to arise [1]. Such data imply that the antibody
response in some individuals is functionally monoclonal and is driving the evolution of
the virus.
4. We Need an Epitope Specificity Test for Antibodies
To determine person-to-person variation in the COVID-19 antibody response, it would
be necessary to determine the epitope specificity of the antibodies stimulated in each
individual. This is a problem that runs all through virology and radical new approaches
are needed to solve it. Currently, mapping of COVID-19-specific antibodies is pretty crude:
antibodies can be assigned to sub-regions of the S protein [15], or more specifically by
binding to overlapping peptides derived from regions of interest on the S protein [16,17],
but neutralization activity can only be inferred, or shown using relevant peptides to deplete
the neutralizing activity of sera [15]. A serious problem is that neutralization epitopes
often comprise non-contiguous/conformational regions within the S protein monomer or
at the interfaces in the trimer, that cannot easily be mimicked by synthetic peptides. An
alternative approach would be to make a panel of multiple escape mutants by sequential
exposure to COVID-19-specific MAbs. These would then be utilised to analyse the epitope
specificity of antibody samples, as used for influenza virus-specific sera [4–6]. At the same
time epitope mapping of COVID-19 S protein would allow an informed evaluation of new
virus variants, as interpretation of the relevance of a new S protein sequence/structure to
the antibody landscape is largely guesswork.
In summary, we lack information about the epitope-specificity of antibodies that
are made in response to COVID-19 infection and vaccines. For protection from variants,
we need individuals to make neutralizing antibodies which are specific for a range of
different epitopes. To understand the evolution of virus variants, we need to know if we
have individuals in the population who, whether from infection or vaccination, make
an extremely narrow antibody response that is effectively monoclonal and can drive the
selection of new variants. Thus, in assessing vaccine efficacy, immunity from infection,
variation between ethnic groups etc we are missing important data. To tackle this problem,
we need first of all to establish the mindset that we have a serious problem here that needs
answering, and then devise the means to quantitatively test for neutralizing antibodies
that react to different epitopes using appropriate high throughput tests.
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